questionsmedicales.fr
Composés chimiques organiques
Acides carboxyliques
Acides acycliques
Acétamides
Lacosamide
Lacosamide : Questions médicales fréquentes
Diagnostic
5
Épilepsie
Électroencéphalographie
Tests sanguins
Évaluation neurologique
Douleur neuropathique
Anticonvulsivants
Crises épileptiques
Douleur neuropathique
Évaluation de l'efficacité
Symptômes
Symptômes
5
Effets secondaires
Nausées
Réactions allergiques
Éruptions cutanées
Changements d'humeur
Dépression
Consultation médicale
Crises épileptiques
Prévention
5
Prévention des crises
Conseils médicaux
Prévention de la douleur
Douleur neuropathique
Sécurité médicamenteuse
Interactions médicamenteuses
Précautions médicales
Maladies cardiaques
Éducation des patients
Effets secondaires
Traitements
5
Administration orale
Voie intraveineuse
Posologie
Anticonvulsivants
Médicaments combinés
Anticonvulsivants
Ajustement de dose
Réponse clinique
Complications
5
Complications
Troubles cardiaques
Dépendance
Anticonvulsivants
Gestion des complications
Professionnels de santé
Fonction cognitive
Troubles cognitifs
Signes de complications
Douleurs thoraciques
Facteurs de risque
5
Facteurs de risque
Effets secondaires
Antécédents médicaux
Maladies cardiaques
Interactions médicamenteuses
Effets indésirables
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lacosamide : Questions médicales les plus fréquentes",
"headline": "Lacosamide : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lacosamide : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-24",
"dateModified": "2026-02-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lacosamide"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Acétamides",
"url": "https://questionsmedicales.fr/mesh/D000081",
"about": {
"@type": "MedicalCondition",
"name": "Acétamides",
"code": {
"@type": "MedicalCode",
"code": "D000081",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.241.081.018.110"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Lacosamide",
"alternateName": "Lacosamide",
"code": {
"@type": "MedicalCode",
"code": "D000078334",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Ali Bozorg",
"url": "https://questionsmedicales.fr/author/Ali%20Bozorg",
"affiliation": {
"@type": "Organization",
"name": "UCB Pharma, Raleigh, NC, USA."
}
},
{
"@type": "Person",
"name": "Svetlana Dimova",
"url": "https://questionsmedicales.fr/author/Svetlana%20Dimova",
"affiliation": {
"@type": "Organization",
"name": "UCB Pharma, Brussels, Belgium."
}
},
{
"@type": "Person",
"name": "Ying Zhang",
"url": "https://questionsmedicales.fr/author/Ying%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "UCB Pharma, Raleigh, NC, USA."
}
},
{
"@type": "Person",
"name": "Robert Roebling",
"url": "https://questionsmedicales.fr/author/Robert%20Roebling",
"affiliation": {
"@type": "Organization",
"name": "UCB Pharma, Monheim am Rhein, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Safety of intravenous lacosamide in hospitalized children and neonates.",
"datePublished": "2023-06-19",
"url": "https://questionsmedicales.fr/article/37287398",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/epi.17676"
}
},
{
"@type": "ScholarlyArticle",
"name": "Investigation of the efficacy and adverse effects of lacosamide over 36 months.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37207404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.yebeh.2023.109227"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database.",
"datePublished": "2024-07-13",
"url": "https://questionsmedicales.fr/article/39003359",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-67209-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy and tolerability of immediate switch from sodium channel blockers to Lacosamide.",
"datePublished": "2023-07-18",
"url": "https://questionsmedicales.fr/article/37473655",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.yebeh.2023.109355"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neonatal Cardiac Arrest Following Lacosamide Treatment: A Case Report.",
"datePublished": "2023-09-15",
"url": "https://questionsmedicales.fr/article/37913565",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pediatrneurol.2023.09.004"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Acides carboxyliques",
"item": "https://questionsmedicales.fr/mesh/D002264"
},
{
"@type": "ListItem",
"position": 4,
"name": "Acides acycliques",
"item": "https://questionsmedicales.fr/mesh/D000144"
},
{
"@type": "ListItem",
"position": 5,
"name": "Acétamides",
"item": "https://questionsmedicales.fr/mesh/D000081"
},
{
"@type": "ListItem",
"position": 6,
"name": "Lacosamide",
"item": "https://questionsmedicales.fr/mesh/D000078334"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lacosamide - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lacosamide",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lacosamide",
"description": "Comment diagnostiquer une épilepsie nécessitant du lacosamide ?\nQuels tests sont nécessaires avant de prescrire du lacosamide ?\nLe lacosamide est-il utilisé pour d'autres conditions ?\nQuels signes cliniques indiquent un besoin de lacosamide ?\nComment évaluer l'efficacité du lacosamide ?",
"url": "https://questionsmedicales.fr/mesh/D000078334#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lacosamide",
"description": "Quels sont les effets secondaires courants du lacosamide ?\nLe lacosamide peut-il provoquer des réactions allergiques ?\nQuels symptômes indiquent une surdose de lacosamide ?\nLe lacosamide affecte-t-il l'humeur ?\nQuels symptômes nécessitent une consultation médicale urgente ?",
"url": "https://questionsmedicales.fr/mesh/D000078334#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lacosamide",
"description": "Comment prévenir les crises chez les patients sous lacosamide ?\nLe lacosamide peut-il prévenir la douleur neuropathique ?\nQuelles mesures de sécurité prendre lors de l'utilisation du lacosamide ?\nLe lacosamide nécessite-t-il des précautions particulières ?\nComment éduquer les patients sur l'utilisation du lacosamide ?",
"url": "https://questionsmedicales.fr/mesh/D000078334#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lacosamide",
"description": "Comment le lacosamide est-il administré ?\nQuelle est la posologie standard du lacosamide ?\nLe lacosamide peut-il être combiné avec d'autres médicaments ?\nComment ajuster la dose de lacosamide ?\nLe lacosamide nécessite-t-il un suivi régulier ?",
"url": "https://questionsmedicales.fr/mesh/D000078334#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lacosamide",
"description": "Quelles complications peuvent survenir avec le lacosamide ?\nLe lacosamide peut-il entraîner une dépendance ?\nComment gérer les complications liées au lacosamide ?\nLe lacosamide peut-il affecter la fonction cognitive ?\nQuels signes indiquent une complication grave ?",
"url": "https://questionsmedicales.fr/mesh/D000078334#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lacosamide",
"description": "Quels facteurs augmentent le risque d'effets secondaires du lacosamide ?\nLe sexe influence-t-il l'efficacité du lacosamide ?\nLes antécédents médicaux influencent-ils l'utilisation du lacosamide ?\nLe mode de vie affecte-t-il l'efficacité du lacosamide ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D000078334#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une épilepsie nécessitant du lacosamide ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical, l'examen neurologique et l'EEG."
}
},
{
"@type": "Question",
"name": "Quels tests sont nécessaires avant de prescrire du lacosamide ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et une évaluation neurologique sont recommandés."
}
},
{
"@type": "Question",
"name": "Le lacosamide est-il utilisé pour d'autres conditions ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est également utilisé pour traiter la douleur neuropathique."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un besoin de lacosamide ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des crises récurrentes et des douleurs neuropathiques persistantes."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du lacosamide ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction des crises et l'amélioration des symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants du lacosamide ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent vertiges, fatigue et nausées."
}
},
{
"@type": "Question",
"name": "Le lacosamide peut-il provoquer des réactions allergiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réactions allergiques comme éruptions cutanées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose de lacosamide ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent confusion, somnolence excessive et troubles de la coordination."
}
},
{
"@type": "Question",
"name": "Le lacosamide affecte-t-il l'humeur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut provoquer des changements d'humeur, y compris dépression ou anxiété."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent une consultation médicale urgente ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des crises sévères ou des réactions allergiques graves."
}
},
{
"@type": "Question",
"name": "Comment prévenir les crises chez les patients sous lacosamide ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Respecter la posologie, éviter les déclencheurs et suivre les conseils médicaux."
}
},
{
"@type": "Question",
"name": "Le lacosamide peut-il prévenir la douleur neuropathique ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est efficace pour réduire la douleur neuropathique chez certains patients."
}
},
{
"@type": "Question",
"name": "Quelles mesures de sécurité prendre lors de l'utilisation du lacosamide ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'alcool et informer le médecin de tout autre médicament pris."
}
},
{
"@type": "Question",
"name": "Le lacosamide nécessite-t-il des précautions particulières ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des précautions sont nécessaires en cas de maladies cardiaques ou rénales."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur l'utilisation du lacosamide ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informer sur les effets secondaires, l'importance de l'adhérence et les signes d'alerte."
}
},
{
"@type": "Question",
"name": "Comment le lacosamide est-il administré ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est administré par voie orale ou intraveineuse, selon la situation."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie standard du lacosamide ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie initiale est généralement de 50 mg deux fois par jour."
}
},
{
"@type": "Question",
"name": "Le lacosamide peut-il être combiné avec d'autres médicaments ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être utilisé avec d'autres anticonvulsivants sous supervision médicale."
}
},
{
"@type": "Question",
"name": "Comment ajuster la dose de lacosamide ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dose peut être ajustée en fonction de la réponse clinique et des effets secondaires."
}
},
{
"@type": "Question",
"name": "Le lacosamide nécessite-t-il un suivi régulier ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour surveiller l'efficacité et les effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le lacosamide ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles cardiaques et des réactions cutanées graves."
}
},
{
"@type": "Question",
"name": "Le lacosamide peut-il entraîner une dépendance ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, le lacosamide n'est pas considéré comme une substance addictive."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées au lacosamide ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications doivent être gérées par un professionnel de santé qualifié."
}
},
{
"@type": "Question",
"name": "Le lacosamide peut-il affecter la fonction cognitive ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut provoquer des troubles cognitifs temporaires chez certains patients."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques, des éruptions cutanées sévères ou des difficultés respiratoires."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires du lacosamide ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les maladies préexistantes et l'utilisation d'autres médicaments."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il l'efficacité du lacosamide ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que l'efficacité peut varier légèrement entre les sexes."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils l'utilisation du lacosamide ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies cardiaques ou rénales peuvent influencer la prescription."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il l'efficacité du lacosamide ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme l'alcool ou le tabac peuvent influencer son efficacité."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions peuvent augmenter le risque d'effets indésirables."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 13/02/2026
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Publications dans "Lacosamide" :
3 publications dans cette catégorie
Affiliations :
UCB Pharma, Raleigh, NC, USA.
Publications dans "Lacosamide" :
3 publications dans cette catégorie
Affiliations :
UCB Pharma, Brussels, Belgium.
Publications dans "Lacosamide" :
3 publications dans cette catégorie
Affiliations :
UCB Pharma, Raleigh, NC, USA.
Publications dans "Lacosamide" :
3 publications dans cette catégorie
Affiliations :
UCB Pharma, Monheim am Rhein, Germany.
Publications dans "Lacosamide" :
3 publications dans cette catégorie
Affiliations :
The National Center for Epilepsy, Sandvika, Oslo University Hospital, Oslo, Norway.
Program for Pharmacy, Department of Life Sciences and Health, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
Publications dans "Lacosamide" :
3 publications dans cette catégorie
Affiliations :
The National Center for Epilepsy, Sandvika, Oslo University Hospital, Oslo, Norway.
Program for Pharmacy, Department of Life Sciences and Health, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
Section for Clinical Pharmacology, Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
Publications dans "Lacosamide" :
3 publications dans cette catégorie
Affiliations :
Epilepsy Center, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Publications dans "Lacosamide" :
3 publications dans cette catégorie
Affiliations :
Neurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Publications dans "Lacosamide" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Aichi Medical University, Nagakute, Aichi, Japan. Electronic address: okumura.akihisa.479@mail.aichi-med-u.ac.jp.
Publications dans "Lacosamide" :
2 publications dans cette catégorie
Affiliations :
UCB Pharma, Brussels, Belgium.
Publications dans "Lacosamide" :
2 publications dans cette catégorie
Affiliations :
Comprehensive Epilepsy Center, Department of Neurology, Wayne State University, Detroit, MI, USA. Electronic address: dzutshi@med.wayne.edu.
Publications dans "Lacosamide" :
2 publications dans cette catégorie
Affiliations :
Comprehensive Epilepsy Center, Department of Neurology, Wayne State University, Detroit, MI, USA.
Publications dans "Lacosamide" :
2 publications dans cette catégorie
Affiliations :
UCB Pharma, Braine-l'Alleud, Belgium.
Publications dans "Lacosamide" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Publications dans "Lacosamide" :
2 publications dans cette catégorie
Publications dans "Lacosamide" :
2 publications dans cette catégorie
Affiliations :
Departments of Neurology and Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Publications dans "Lacosamide" :
2 publications dans cette catégorie
Publications dans "Lacosamide" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Children's Hospital Colorado, Aurora, Colorado, USA.
Publications dans "Lacosamide" :
2 publications dans cette catégorie
Affiliations :
UCB Pharma, Raleigh, North Carolina, USA.
Publications dans "Lacosamide" :
Seizures are common in critically ill children and neonates, and these patients would benefit from intravenous (IV) antiseizure medications with few adverse effects. We aimed to assess the safety prof...
This retrospective multicenter cohort study examined the safety of IV LCM use in 686 children and 28 neonates who received care between January 2009 and February 2020....
Adverse events (AEs) were attributed to LCM in only 1.5% (10 of 686) of children, including rash (n = 3, .4%), somnolence (n = 2, .3%), and bradycardia, prolonged QT interval, pancreatitis, vomiting, ...
This large observational study provides novel evidence demonstrating the tolerability of IV LCM in children and neonates....
To evaluate the efficacy and retention rate of lacosamide (LCM) over 36 months as a treatment for children and adolescents with focal and generalized epilepsy based on a retrospective study....
All patients prescribed LCM as monotherapy and add-on therapy between October 2016 and September 2019 at Jichi Children's Medical Center Tochigi were included in the study. The response rate, retentio...
A total of 126 (female, n = 73) patients of 1.3 to 34.9 years old (median age: 12.8 years; mean ± SD 13.2 ± 6.6 years) received LCM as monotherapy or add-on treatment for focal, generalized, and combi...
Our response rate was lower and our retention rate was higher in comparison to a previous study that observed patients over 36 months. Further prospective studies in children are required to confirm t...
Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large samples still need to be completed. We evaluated the ca...
Lacosamide (LCM) is a new-generation anti-seizure medication approved for monotherapy and add-on therapy for focal-onset epilepsy. It has novel pharmacodynamics and favorable pharmacokinetic qualities...
Lacosamide is an antiepileptic drug with US Food and Drug Administration approval for the treatment of partial-onset seizures in patients older than one month. Lacosamide works by selective enhancemen...
We present the case of a three-week-old female neonatal patient born at 25 weeks' gestation who developed second-degree AV heart block and cardiac arrest after initiating lacosamide therapy. The patie...
Use of lacosamide for neonatal populations is currently under evaluation. This is the first report of adverse cardiac event (AV block) in the setting of neonatal lacosamide use. Risk of future adverse...
The purpose of this study was to determine the efficacy of lacosamide (LCM) on interictal epileptiform discharges (IEDs) and evaluate the relationships between IEDs and seizure outcome in pediatric pa...
Patient inclusion criteria included (1) newly diagnosed focal epilepsy with unknown etiology; and (2) electroencephalogram recorded twice (before and after starting LCM) under the same conditions. The...
Of 22 patients, 10 showed an increase in IEDs/5 min after starting LCM. The median IEDs/5 min before and after starting LCM was not significantly different, at 1.5 (interquartile range: 0, 31.75) and ...
The effects of LCM on the number of IEDs may be unrelated to seizure outcome. LCM may be ineffective at improving seizure outcomes in patients with multiple regional or diffuse IEDs....
We aimed to evaluate the effect of the ABCC2 1249G>A (rs2273697) and -24C>T (rs717620) polymorphisms on lacosamide (LCM) plasma concentrations and the efficacy of LCM in Uygur pediatric patients with ...
We analyzed 231 pediatric patients with epilepsy, among which 166 were considered to be LCM responsive. For drug assays, 2-3 mL of venous blood was collected from each patient just before the morning ...
Patients with the ABCC2 1249G>A GA genotype (0.7 ± 0.3 mcg/mL per kg/mg) and AA genotype (0.5 ± 0.3 mcg/mL per kg/mg) showed significantly ( P < 0.001) lower LCM concentration-to-dose (CD) ratios than...
The ABCC2 1249G>A (rs2273697) and ABCC2 -24C>T (rs717620) polymorphisms can affect plasma LCM concentrations and treatment efficacy among a population of Uygur pediatric patients with epilepsy, causin...
Perampanel (PER) and lacosamide (LCM) are the new third-generation anti-seizure medications (ASMs) that were approved for the monotherapy of focal epilepsy in children over four years of age in China,...
This was a prospective, single-center, observational study that involved pediatric patients (disease onset age ≥four years) with newly diagnosed focal epilepsy treated with PER or LCM as primary monot...
Using randomization, 60 patients receiving PER (31 females, 29 males, median age: 7.79 [5.34, 10.16] years, median dose: 3.0 [2.0, 4.0] mg/day) and 60 patients receiving LCM (25 females, 35 males, med...
The present study documented similar good effectiveness and good tolerance of PER and LCM as monotherapy in pediatric patients with newly diagnosed focal epilepsy and showed no behavioral or emotional...
The effectiveness and tolerability of lacosamide (LCM) among Chinese children and adolescents with refractory epilepsy has not yet been established. Therefore, the objective of this study was to asses...
Effectiveness was assessed by measuring changes in seizure frequency at 3, 6 and 12 months compared with baseline. Patients that achieved ≥ 50% reduction in the frequency of all seizures per month, re...
105 children and adolescents with refractory epilepsy were enrolled in the study. The responder rates were 47.6%, 39.2%, and 31.9%, respectively at 3, 6, and 12 months. Seizure freedom rates were 32.4...
This real-world study of children and adolescents validated that LCM was both an effective and well-tolerated treatment option for the treatment of refractory epilepsy....
Lacosamide is licensed for the treatment of focal seizures in both adults and children, however there is little information available on its adverse reactions. Using the FDA Adverse Event Reporting Sy...
On the basis of the FAERS database from the fourth quarter of 2008 to the second quarter of 2022, disproportionality analysis was carried out using the reporting odds ratio (ROR) method, the United Ki...
A total of 10,226 adverse reaction reports with Lacosamide as the primary suspect drug were obtained, with 30,960 reported cases, detecting 232 valuable positive signals, involving a total of 20 SOCs,...
Our research demonstrates that the clinical use of Lacosamide should be noticed and avoided in relation to ADRs since it raises the risk of cardiac arrest, ventricular fibrillation, stevens-johnson sy...